The Incidence of Skin and Soft Tissue Infections in the United States and Associated Healthcare Utilization Between 2010 and 2020
Open Forum Infectious Diseases · 03.06.2024 · 11 (6)
DOI: 10.1093/ofid/ofae267 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 07.05.2024. Verfasst von Venanzio Vella und 6 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Epidemiology-Bacterial, GSK, Siena, Italy. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Biologicals SA.
Abstract (Originalsprache)
Background
The number of patients with skin and soft tissue infections (SSTIs) in the United States appeared to be increasing well into the 21st century. However, no recent data have confirmed this trend.
Methods
This retrospective, observational cohort study used claims data over 11 years (2010–2020) from Optum's de-identified Clinformatics Data Mart Database. SSTI episodes, complications, and comorbidities were identified using International Classification of Diseases codes. Annual SSTI incidence rates, proportions of recurrent SSTI, SSTI-associated deaths, and total costs were estimated.
Results
During the study period, 5.4 million patients experienced 9.1 million SSTI episodes, with an incidence of 77.5 (95% confidence interval, 77.4–77.5) per 1000 person-years of observation (PYO). Annual incidence did not change significantly over time. Overall incidence (per 1000 PYO) of SSTI episodes in patients without comorbidities was 32.1 (highest incidence was for previous SSTI [113.5]) versus much higher rates if comorbidities were present. Incidence rates (per 1000 PYO) of chronic ulcers increased over time from 11.3 to 18.2 (P < .0001) and complicated disease from 3.5 to 6.3 (P < .0001). Deaths occurring within 30 days post–SSTI hospitalization rose from 2.6% to 4.6% in 2020. Recurrences occurred in 26.3% of index cases. The mean cost of an SSTI episode was US$3334 (median US$190) and was highest for surgical site infections and chronic ulcers.
Conclusions
The epidemiology of SSTI in the United States is changing and the disease burden is increasing despite stabilization in overall incidence. These data can inform identification of priority populations who could benefit from targeted interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vaccine Epidemiology-Bacterial, GSK, Siena, Italy.
- Real World Analytics, GSK, Wavre, Belgium.
- Vaccines Clinical Sciences, GSK, Siena, Italy.
- Early Bacterial Vaccine Program, GSK, Siena, Italy.
- Global Medical Affairs, GSK, Wavre, Belgium.
- Infectious Diseases Research Unit, GSK, Siena, Italy.
ORCID-Profile: Venanzio Vella, Emmanuel Aris, Michele Pellegrini, Michael Scherbakov
Förderung
- GlaxoSmithKline Biologicals SA
Zitieren
APA
Vella, V., Derreumaux, D., Aris, E., Pellegrini, M., Contorni, M., Scherbakov, M., & Bagnoli, F. (2024). The Incidence of Skin and Soft Tissue Infections in the United States and Associated Healthcare Utilization Between 2010 and 2020. Open Forum Infectious Diseases, 11(6). https://doi.org/10.1093/ofid/ofae267
Vancouver
Vella V, Derreumaux D, Aris E, Pellegrini M, Contorni M, Scherbakov M, et al. The Incidence of Skin and Soft Tissue Infections in the United States and Associated Healthcare Utilization Between 2010 and 2020. Open Forum Infectious Diseases. 2024;11(6). doi:10.1093/ofid/ofae267
BibTeX
@article{Vella2024,
author = {Vella, Venanzio and Derreumaux, Dominique and Aris, Emmanuel and Pellegrini, Michele and Contorni, Mario and Scherbakov, Michael and Bagnoli, Fabio},
title = {The Incidence of Skin and Soft Tissue Infections in the United States and Associated Healthcare Utilization Between 2010 and 2020},
journal = {Open Forum Infectious Diseases},
year = {2024},
volume = {11},
number = {6},
doi = {10.1093/ofid/ofae267}
}
EUVIMED